Several molecular targets are being explored to target TNBC, including the androgen receptor, epidermal growth factor receptor (EGFR), poly (ADP-ribose) polymerase (PARP), and vascular endothelial growth factor (VEGF) [2] TNBC accounts for approximately 15–20% of BC. This evidence concerns the gene EGFR and breast cancer.